GGrantIndex
Sort

48,018 grants matching immunotherapy

MICROFLUIDIC DIAGNOSTICS FOR MONITORING OF BRAF INHIBITOR RESISTANCE IN MELANOMA

$476,399
Hsian-Rong Tseng · University Of California Los Angeles · P01 · FY2015 · CA

Developmental Funds

$476,285
Steven K. Libutti · Rbhs -Cancer Institute Of New Jersey · P30 · FY2021 · CA

Developmental Funds

$476,270
Steven K. Libutti · Rbhs -Cancer Institute Of New Jersey · P30 · FY2020 · CA

Cytokines driving T cell dysregulation in lacrimal gland autoimmunity

$476,248
Scott Matthew Lieberman · University Of Iowa · R01 · FY2021 · EY

Clinical Core

$476,136
Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2012 · CA

Iron oxide nanotheranostics for breast cancer

$476,097
Miqin Zhang · University Of Washington · R01 · FY2021 · EB

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradication

$476,070
Dimitra Peppa · University Of Oxford · R01 · FY2020 · AI

Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer

$476,037
Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA

Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines

$476,018
Xuefei Huang · Michigan State University · R01 · FY2012 · CA

Enhancing HSPC CAR-mediated immunity in vivo

$475,999
Scott G Kitchen · University Of California Los Angeles · U19 · FY2022 · AI

Project 3: Phase-2 Trial of Oncolytic Poliovirus (PVSRIPO) combined with CCNU (lomustine) against Recurrent Glioblastoma

$475,986
Darell D Bigner · Duke University · P01 · FY2019 · CA

Project-002

$475,984
Margaret M Madeleine · Fred Hutchinson Cancer Center · U54 · FY2023 · CA

IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES

$475,945
Stanford University · R01 · FY2000 · NS

Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma

$475,922
Jessie Villanueva · Wistar Institute · R01 · FY2023 · CA

Gonorrhea and HIV prevention with intravaginal ring drug delivery

$475,901
Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R33 · FY2021 · AI

Novel roles of STAT2 and IFN-I in tumorigenesis and responses to therapy

$475,893
George Robert Stark · Cleveland Clinic Lerner Com-Cwru · P01 · FY2023 · CA

Clinical production of viral vectors for cancer gene therapy

$475,840
Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2012 · CA

Autophagy proteins in the immune response to Mycobacterium tuberculosis infection

$475,781
Christina Leigh Stallings · Washington University · R01 · FY2019 · AI

Analysis of galectin-8 and its ligands in melanoma progression

$475,743
Charles J Dimitroff · Florida International University · R01 · FY2024 · CA

Biodegradable Polymer Nanodiscs as Novel Lipoprotein-Mimicking Nanocarriers for Anticancer Drug Delivery with High Stability and Long Circulation Time

$475,726
Hongjun Liang · Texas Tech University Health Science Center · · FY2022 · MPS

Duke-UNC Chapel Hill Immunotherapy Training Grant

$475,705
Jonathan Stuart Serody · Univ Of North Carolina Chapel Hill · T32 · FY2019 · CA

Project 1: Delta immune Ecology of NSCLC

$475,697
Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2024 · CA

Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer

$475,682
Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2022 · CA

Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer

$475,682
Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2023 · CA

Development of new treatments for rare CNS tumors

$475,654
Marta Penas-Prado · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA